UBS Group
KRBP

UBS Group’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

UBS Group’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,222
Closed -$4.72K – 10411
2023
Q1 		$4.72K Sell
1,222
-70
-5% -$370 ﹤0.01% 8155
2022
Q4 		$6.98K Buy
1,292
+675
+109% +$5.42K ﹤0.01% 8958
2022
Q3 		$5K Buy
617
+445
+259% +$5.16K ﹤0.01% 9287
2022
Q2 		$2K Sell
172
-528
-75% -$8.33K ﹤0.01% 9733
2022
Q1 		$18K Buy
700
+603
+622% +$17.8K ﹤0.01% 7612
2021
Q4 		$4K Buy
+97
New +$6.61K ﹤0.01% 9594
2021
Q2 		– Sell
-58
Closed -$16K – 10071
2021
Q1 		$16K Hold
58
– – ﹤0.01% 7594
2020
Q4 		$15K Buy
+58
New +$16.5K ﹤0.01% 7188

Other funds holding KRBP

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group's KRBP Position: Q2 2023 in Review

UBS Group sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q2 2023, closing a stake of 1,222 shares — an estimated $4.72K sold.

UBS Group first reported a position in KRBP in Q4 2020 and held it in 8 quarters. The position peaked at $18K in Q1 2022. 5 funds tracked by Wall St. Rank hold KRBP as of Q2 2023.

  • UBS Group reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 1,222 Kiromic BioPharma, Inc. Common Stock shares in Q2 2023, an estimated $4.72K.
  • UBS Group first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
  • UBS Group's Kiromic BioPharma, Inc. Common Stock position peaked at $18K in Q1 2022.
  • 5 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.